CPUY074020;3-(1-Piperidyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]-6H-anthra[1,9-cd]isoxazol-6-one;6H-Anthra[1,9-cd]isoxazol-6-one, 3-(1-piperidinyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]-;CPUY074020,CPUY-074020;CPUY074020, 10 mM in DMSO;3-(1-Piperidinyl)-5-[[2-(1-pyrrolidinyl)ethyl]amino]-6H-anthra[1,9-cd]isoxazol-6-one
CPUY074020 is a potent, orally active inhibitor of the histone methyltransferase G9a (IC50 = 2.18 μM) with antiproliferative activity; it induces apoptosis in cancer cells (e.g., MCF-7 cells) and dose-dependently downregulates H3K9 trimethylation; it exhibits favorable pharmacokinetic properties in vivo, including an oral bioavailability of 55.5% and a half-life (t1/2) of 4.0 hours at an oral dose of 10 mg/kg in mice.